达格列净联合二甲双胍缓释片治疗2型糖尿病的效果

Effect of Dapagliflozin Combined with Metformin Sustained-release Tablets in the Treatment of Type 2 Diabetes Mellitus

目的:研究达格列净联合二甲双胍缓释片对2型糖尿病患者血糖控制优良率、血糖水平、安全性的影响。方法:选取2021年1月—2023年12月我院接受治疗的180例2型糖尿病患者,经随机抽签方法分为观察组(94例)和对照组(86例)。对照组单纯应用二甲双胍缓释片口服,观察组在对照组基础上联合达格列净口服,比较两组血糖控制优良率、随机血糖、糖化血红蛋白、不良反应发生率。结果:(1)观察组(87.23%)的血糖控制优良率高于对照组(72.09%),差异有统计学意义(P<0.05);(2)观察组用药后随机血糖和糖化血红蛋白低于对照组,差异有统计学意义(P<0.05);(3)观察组(8.51%)的不良反应发生率和对照组(8.14%)比较,差异无统计学意义(P>0.05)。结论:对2型糖尿病患者采用达格列净联合二甲双胍缓释片治疗不会产生严重的用药不良反应,可以提升患者血糖的控制优良率,并稳定患者的血糖水平,值得临床应用。

Objective:To investigate the impact of Dapagliflozin combined with Metformin Hydrochloride Extended-Release Tablets on the excellent and good rate of blood glucose control,blood glucose levels,and safety in patients with type 2 diabetes mellitus.Methods:A total of 180 patients with type 2 diabetes mellitus who received treatment at our hospital from January 2021 to December 2023 were selected and randomly divided into an observation group(94 patients)and a control group(86 patients)using a random lottery method.The control group received oral administration of Metformin hydrochloride extended-release tablets alone,while the observation group received oral dapagliflozin in addition to the control group’s treatment.The excellent and good rate of blood glucose control,random blood glucose,glycated hemoglobin,and the incidence of adverse reactions were compared between the two groups.Results:①The excellent and good rate of blood glucose control in the observation group(87.23%)was higher than that in the control group(72.09%),with a statistically significant difference(P<0.05).②After treatment,the observation group had lower random blood glucose and glycated hemoglobin levels compared to the control group,with statistically significant differences(P<0.05).③There was no statistically significant difference in the incidence of adverse reactions between the observation group(8.51%)and the control group(8.14%)(P>0.05).Conclusion:The treatment of type 2 diabetes mellitus patients with dapagliflozin combined with metformin hydrochloride extended-release tablets does not result in serious adverse drug reactions.It can improve the excellent and good rate of blood glucose control and stabilize blood glucose levels in patients,making it worthy of clinical application.